MORE►
biotech
Ben Lamm is co-founder of Astromech. [Photo: Astromech]
Astromech Raises $20M for Next Phase of Bringing AI to Evolutionary Biology
by Lauren Lawley Head | Aug 20, 2026
The Dallas-based Colossal Biosciences spinout, now valued at $3.8 billion, is preparing forecasting pilots in health and biosecurity as it scales the model behind its predictions.
by Sandra Engelland |
Jul 7, 2026
By using a vaccine and gene editing, the partners aim to fight a lethal cancer that has reduced the wild population of Tasmanian devils by 80% since the 1990s.
MORE►
by Lauren Lawley Head |
Jul 6, 2026
“We are giving physicians and patients a powerful new tool to help identify cancer earlier and support more informed clinical decisions,” CEO David Dean Halbert says of Caris Detect.
MORE►
by Maddie Preston |
Feb 3, 2026
A UT Dallas study supports Allen-based EnLiSense’s approach to circadian health monitoring, via a wearable that directly measures biochemical markers tied to wakefulness and sleep.
MORE►
Ribbon-cutting ceremony for the National Center for Therapeutics Manufacturing satellite campus [Photo: UTA]
UTA, Texas A&M TEES Open Biomanufacturing Training and Research Hub at Pegasus Park
by Maddie Preston | Dec 23, 2025
A new satellite campus is adding hands-on training, lab capacity and startup support to Dallas’ growing life sciences ecosystem.
MORE►
by Quincy Preston |
Nov 5, 2025
Cait Brumme says the event at Dallas' Pegasus Park on Nov. 6 will explore the technologies and economic forces defining the future for entrepreneurs and innovators.
MORE►
by Quincy Preston |
Nov 4, 2025
The de-extinction startup is adding more than two decades of commercial cloning expertise to its portfolio with its first acquisition.
Days before the announcement, CEO Ben Lamm laid out his playbook at Venture Dallas 2025: run toward critics, treat promises to middle-America classrooms as seriously as commitments to investors—and spin out businesses worth more than $100 million.
MORE►
by David Seeley |
Oct 23, 2025
The Palo Alto-based company's new Dallas facility is its first dedicated U.S. laboratory, and will serve as its U.S. clinical operations headquarters. Overture's AI-driven IVF technology gives fertility teams "objective data to inform embryo selection without a biopsy," the company said, "allowing clinics to process three times the number of procedures without adding staff."
MORE►
Researchers at UT Dallas used an enzyme called TdT to create unique genetic "fingerprints" inside living cells—a breakthrough in biosecurity that could help biotech companies verify cell identity and prevent counterfeiting. The technique, published in Advanced Science, increases randomness in DNA repair to generate one-of-a-kind markers. This cropped image shows a key step—Pol X’s role in the process. [Source: Figure 1, TdT (1D) PUF/Advanced Science]
UT Dallas Researchers ‘Barcode’ Engineered Cells with Patent-Pending Tech to Protect Biotech IP
by Maddie Preston | Sep 27, 2025
The UTD team’s approach adapts a chip-security technique to biology. The breakthrough gives biotech companies a new way to prevent costly misidentification and protect intellectual property.
MORE►
by Glenn Hunter |
Sep 24, 2025
At Dallas’ iC3 Summit, leaders from Texas and across the U.S. pointed to AI, new state initiatives like Proposition 14, and potential federal reforms as keys to speeding innovation and keeping America competitive in life sciences.
MORE►
by Lance Murray |
Aug 28, 2025
The Pittsburgh-headquartered nonprofit's executive director, Dallas-based Gina Ford, takes up the newly created top post of the organization, which empowers women across biotech, pharma, and life sciences to lead, engage, and grow at every career stage.
MORE►
by Quincy Preston |
Jul 15, 2025
North Texas' Nanoscope just filed an FDA bid for its gene-agnostic therapy. If approved, it could help restore sight for people with inherited blindness, and potentially millions more with other retinal diseases.
MORE►
![The South Island giant moa towered over New Zealand's forests for millions of years before becoming extinct within a century of Polynesian settlement around 1400 CE. Colossal Biosciences plans to resurrect the 500-pound birds using ancient DNA extracted from cave deposits and artificial egg technology. [Source image: Colossal Biosciences]](https://s24806.pcdn.co/wp-content/uploads/2025/07/Colossal-Moa-940x436.jpg)
The South Island giant moa towered over New Zealand's forests for millions of years before becoming extinct within a century of Polynesian settlement around 1400 CE. Colossal Biosciences plans to resurrect the 500-pound birds using ancient DNA extracted from cave deposits and artificial egg technology. [Source image: Colossal Biosciences]
Colossal Biosciences Takes On De‑Extinction of New Zealand’s 12‑Foot Moa After Dire Wolf Milestone
by Quincy Preston | Jul 9, 2025
The Dallas decacorn is scaling its de-extinction pipeline with indigenous leadership, a New Zealand subsidiary, and economic models for species preservation, including ecotourism opportunities. Filmmaker Sir Peter Jackson helped connect the collaborators, Colossal CEO Ben Lamm says.
MORE►
by Lance Murray |
Jun 5, 2025
Co-founded by Chief Scientific Advisor Daniel J. Siegwart of UT Southwestern and CEO RA Session II, Signify Bio said it harnesses the human body for the production of in situ protein therapeutics. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge, the American Cancer Society's VC arm.
MORE►
by Lance Murray |
May 8, 2025
Eric Matthews will provide strategic leadership to biopharma business development, and through his executive leadership, support Caris' expanding portfolio of biopharma partnerships, the company said.
MORE►
by Quincy Preston |
Apr 24, 2025
Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress—the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.
MORE►
